Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, D. Caillot et al.|Blood|2025Cited by 34
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Aurore Perrot, Cyrille Hulin et al.|Blood Cancer Journal|2025Cited by 2